Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review.

Hypoglycemia Multicentric insulinomas Pancreatic neuroendocrine tumors Somatostatin analogs

Journal

Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142

Informations de publication

Date de publication:
15 Jul 2022
Historique:
received: 18 05 2022
accepted: 06 07 2022
entrez: 15 7 2022
pubmed: 16 7 2022
medline: 16 7 2022
Statut: epublish

Résumé

Hyperinsulinemic hypoglycemia is most commonly caused by a single, sporadic insulinoma. Multicentric insulinoma disease (insulinomatosis) as well as metachronous neuroendocrine tumors of the pancreas, known also as neuroendocrine adenomatosis, represent a very rare condition, if not associated with multiple endocrine neoplasia type 1 syndrome (MEN1) or Von Hippel Lindau disease. We report a 9-year follow-up of a 41-year-old woman, initially presenting with hypoglycemic syndrome caused by two insulin-producing tumors, who underwent subtotal pancreasectomy in 2012, with histology compatible with multiple small neuroendocrine tumors. An approximately 1-cm insulin-producing tumor recurred at subsequent biochemical and radiological follow-up, and was cured with the somatostatin analog octreotide as a single treatment, until remission of symptoms and complete regression of the pancreatic lesion achieved after only 16 months of treatment. The possible mechanisms for these findings are discussed and the literature is briefly reviewed.

Identifiants

pubmed: 35838801
doi: 10.1007/s12672-022-00531-z
pii: 10.1007/s12672-022-00531-z
pmc: PMC9287506
doi:

Types de publication

Journal Article

Langues

eng

Pagination

66

Informations de copyright

© 2022. The Author(s).

Références

Endocr Metab Immune Disord Drug Targets. 2018;18(5):419-449
pubmed: 29237387
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1027-1032
pubmed: 29339498
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
J Clin Endocrinol Metab. 2009 Mar;94(3):709-28
pubmed: 19088155
J Clin Endocrinol Metab. 2009 Apr;94(4):1069-73
pubmed: 19141587
Int J Mol Sci. 2020 Feb 29;21(5):
pubmed: 32121432
Am J Surg Pathol. 2009 Mar;33(3):339-46
pubmed: 19011561
Diagn Cytopathol. 2017 Feb;45(2):143-147
pubmed: 27670143
Endocr Pathol. 2014 Jun;25(2):181-5
pubmed: 24718881
Pancreas. 2016 Jan;45(1):154-9
pubmed: 26658039
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Eur J Endocrinol. 2005 May;152(5):757-67
pubmed: 15879362
N Engl J Med. 2000 Aug 24;343(8):551-4
pubmed: 10954763
World J Surg. 1993 Jul-Aug;17(4):504-10
pubmed: 8395751
J Clin Endocrinol Metab. 2016 Oct;101(10):3559-3563
pubmed: 27504852
Endocr Relat Cancer. 2016 Mar;23(3):191-9
pubmed: 26743120
Eur J Endocrinol. 2007 Jul;157(1):75-83
pubmed: 17609405
J Clin Endocrinol Metab. 2000 Sep;85(9):3222-6
pubmed: 10999812

Auteurs

Andreas Tartaglia (A)

Unit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy. a.tartaglia@ausl.fo.it.

Giulia Busonero (G)

Unit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.

Lorenza Gagliardi (L)

Unit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.

Valentina Boddi (V)

Unit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.

Federica Pieri (F)

Unit of Pathology, Morgagni Hospital, Forlì, Italy.

Maurizio Nizzoli (M)

Unit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.

Classifications MeSH